Listed by the USPTO as HOLLAND, PAUL J
Tech Center 1700 • Art Units: 1636 1651 1653 1656 1761
This examiner grants 57% of resolved cases
Paul J. Holland has processed 785 resolved cases in Tech Center 1700 and Art Unit 1636. His allowance rate is 57.3 percent, and the interview lift is 64.7 percent. This 64.7 percent lift is a very high indicator of the effectiveness of interviews in his docket.
The median days to allowance is 1095. Major entities appearing before him include Halozyme Inc., Pairwise Plants Services Inc., and Metagenomi Inc. Top firms include Haynes Beffel & Wolfeld LLP, Kagan Binder, PLLC, and Knobbe, Martens, Olson & Bear, LLP.
The 57.3 percent allowance rate and 1095-day median pendency are based on 785 resolved cases. The 64.7 percent interview lift is a critical factor for practitioners to consider. These metrics provide a clear benchmark for prosecution in Art Unit 1636.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17826545 | CELL CULTURE METHOD, ANTIBODY PRODUCTION METHOD, ORGANIC ACID REMOVAL METHOD, AND ANTIBODY | Final Rejection | FUJIFILM Corporation |
| 19550132 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | Final Rejection | Halozyme, Inc. |
| 19550136 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | Non-Final OA | Halozyme, Inc. |
| 18882496 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | Non-Final OA | Halozyme, Inc. |
| 18501344 | DETERGENT COMPOSITIONS CONTAINING A BRANCHED SURFACTANT, A XYLOGLUCANASE AND A PERFUME | Non-Final OA | The Procter & Gamble Company |
| 17820488 | RETINAL ORGANOID MODEL SYSTEMS | Final Rejection | Wisconsin Alumni Research Foundation |
| 18278695 | METHODS FOR GENERATING A CRISPR ARRAY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18143492 | Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP) | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18681252 | ISOLATION OF THERAPEUTIC PROTEIN | Final Rejection | Amgen Inc. |
| 18282782 | METHODS FOR RECOMBINANT PROTEIN EXPRESSION IN EUKARYOTIC CELLS | Non-Final OA | Wageningen Universiteit |
| 18185601 | METHODS AND COMPOSITIONS FOR INTEGRATION OF A DNA CONSTRUCT | Non-Final OA | New York University |
| 17604714 | METHODS OF IMPROVING THE LONGEVITY OF IMMUNE CELLS | Final Rejection | University of Houston System |
| 17921035 | CHIMERIC POLYPEPTIDES AND METHODS OF PREPARING SAME | Final Rejection | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18275587 | PROTEIN DEAMIDATING ENZYME | Final Rejection | AMANO ENZYME INC. |
| 18556393 | TWO-STAGE DYNAMIC CONTROL OVER REDOX STATE IMPROVES CYSTOLIC EXPRESSION OF DISULFIDE CONTAINING PROETEINS IN E. COLI | Non-Final OA | Duke University |
| 18691573 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18329520 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | Non-Final OA | Octapharma AG |
| 18329503 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | Non-Final OA | Octapharma AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.3% of resolved applications examined by Paul J Holland were allowed (785 resolved cases), compared with 37.1% across Art Unit 1636 over the last five years.
This examiner's interview lift is +64.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Paul J Holland took 1,095 days on average from filing to allowance.
Paul J Holland examines applications in Art Unit 1636 in Tech Center 1700 (Chemistry & Materials).
